<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336854</url>
  </required_header>
  <id_info>
    <org_study_id>111HPS14027</org_study_id>
    <nct_id>NCT02336854</nct_id>
  </id_info>
  <brief_title>Tacrobell tab_Phase1_PK</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      A randomized, open-label, two-way crossover study to assess the tolerability and&#xD;
      pharmacokinetics of Tacrobell® Tab. and Prograf® Cap. after a single oral dose in healthy&#xD;
      male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Actual">March 19, 2015</completion_date>
  <primary_completion_date type="Actual">February 2, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Immunosuppressant(Organ Transplantation, RA)</condition>
  <arm_group>
    <arm_group_label>Tacrobell tab. 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/tablet, PO, 1 tablet once daily for Period I &amp; II D1(crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf cap. 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1mg/capsule, PO, 2 capsule once daily for Period I &amp; II D1(crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrobell tab. 2mg</intervention_name>
    <arm_group_label>Tacrobell tab. 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf cap. 2mg</intervention_name>
    <arm_group_label>Prograf cap. 2mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand the requirements of the study and voluntarily consent to participate in the&#xD;
             study.&#xD;
&#xD;
          2. Healthy male volunteer in the age between 20 and 45 years old.&#xD;
&#xD;
          3. Body weight ≥ 55 kg and 30.0kg/m2 ≥ BMI ≥ 18.0kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. presence or a history of clinically significant cardiovascular, renal, hepatic,&#xD;
             pulmonary, metabolic, endocrine, hematological, gastrointestinal, neurological,&#xD;
             psychiatric or other diseases&#xD;
&#xD;
          2. any chronic disease which might interfere with resorption, distribution, metabolism or&#xD;
             excretion of the drug, or major surgery of the gastrointestinal tract except for&#xD;
             appendectomy&#xD;
&#xD;
          3. any history of drug hypersensitivity (especially to the active and inactive&#xD;
             ingredients of the tacrolimus preparation)&#xD;
&#xD;
          4. administration of cyclosporine or Bosentan&#xD;
&#xD;
          5. administration of potassium sparing diuretic&#xD;
&#xD;
          6. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption&#xD;
&#xD;
          7. SBP &gt; 150 mmHg or&lt; 90 mmHg&#xD;
&#xD;
          8. DBP &gt; 100 mmHg or &lt; 50 mmHg&#xD;
&#xD;
          9. positive serologic findings for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies, RPR&#xD;
&#xD;
         10. AST or ALT &gt; 1.5*ULN, e-GFR &lt; 80 mL/min&#xD;
&#xD;
         11. history of drug abuse or positive drug screening test&#xD;
&#xD;
         12. intake or administration of any ethical or herbal medication medication within 2&#xD;
             weeks, intake or administration of any OTC or vitamin preparations&#xD;
&#xD;
         13. medication with metabolizing enzyme inducers or inhibitors such as barbitals within 1&#xD;
             month before first dosing&#xD;
&#xD;
         14. administration of another study medications within 3 months before first dosing&#xD;
&#xD;
         15. blood donation in 2 months, component blood donation within 1 month or blood&#xD;
             transfusion before first dosing&#xD;
&#xD;
         16. Alcohol &gt; 21 units/week or cannot stop drinking during the study&#xD;
&#xD;
         17. Cigarette &gt; 10 cigarettes/day or cannot stop smoking during hospitalization&#xD;
&#xD;
         18. consumption of beverages or food containing caffeine(e.g.coffee, tea) during&#xD;
             hospitalization&#xD;
&#xD;
         19. consumption of grapefruit or food containing grapefruit during hospitalization&#xD;
&#xD;
         20. Not eligible to participate for the study at the discretion of investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

